Список литературы к Главе 7

1. Müller­Hermelink H.K., Montserrat E., Catovsky D., Campo E., Harris N.L., Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma // World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues / eds S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein et al. Lyon : IARC, 2008. P. 180–182.

2. Rossi D., Gaidano G. Richter syndrome: pathogenesis and management // Semin. Oncol. 2016. Vol. 43, N 2. P. 311–319.

3. Rossi D., Spina V., Gaidano G. Biology and treatment of Richter syndrome // Blood. 2018. Vol. 131, N 25. P. 2761–2772.

4. Giné E., Martinez A., Villamor N. et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia («accelerated» chronic lymphocytic leukemia) with aggressive clinical behavior // Haematologica. 2010. Vol. 95. P. 1526–1533.

5. Soilleux E.J., Wotherspoon A., Eyre T.A., Clifford R., Cabes M., Schuh A.H. Diagnostic dilemmas of high­grade transformation (Richter’s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP­OR clinical trial specialist haemato­pathology central review // Histopathology. 2016. Vol. 69. P. 1066–1076.

6. Rossi D., Spina V., Deambrogi C. et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation // Blood. 2011. Vol. 117. P. 3391–3401.

7. He R., Ding W., Viswanatha D. et al. PD­1 expression in chronic lymphocytic leukemia and large B­cell richter transformation (DLBCL­RT): a distinguishing feature for DLBCL­RT and promising surrogate marker for clonal relatedness // Blood. 2017. Vol. 130. Abstr. 4286.

8. Mao Z., Quintanilla­Martinez L., Raffeld M. et al. IgVH mutational status and clonality analysis of Richter’s transformation // Am. J. Surg. Pathol. 2007. Vol. 31. P. 1605–1614.

9. Anderson M.A., Tam C., Lew T.E. et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax // Blood. 2017. Vol. 129, N 25. P. 3362–3370.

10. Xiao W., Chen W.W., Sorbara L. et al. Hodgkin lymphoma variant of Richter transformation: morphology, Epstein­Barr virus status, clonality, and survival analysis­with comparison to Hodgkin­like lesion // Hum. Pathol. 2016. Vol. 55. P. 108–116.

11. Fabbri G., Khiabanian H., Holmes A.B. et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome // J. Exp. Med. 2013. Vol. 210. P. 2273–2288.

12. Chigrinova E., Rinaldi A., Kwee I. et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome // Blood. 2013. Vol. 122. P. 2673–2782.

13. Rossi D., Berra E., Cerri M. et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B­cell lymphoma // Haematologica. 2006. Vol. 91. P. 1405–1409.

14. De Paoli L., Cerri M., Monti S. et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia // Leuk. Lymphoma. 2013. Vol. 54. P. 1087–1090.

15. Fabbri G., Rasi S., Rossi D. et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation // J. Exp. Med. 2011. Vol. 208. P. 1389–1401.

16. Puente X.S., Pinyol M., Quesada V. et al. Whole­genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia // Nature. 2011. Vol. 475. P. 101–105.

17. Fabbri G., Holmes A.B., Viganotti M. et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 2017. Vol. 114, N 14. P. E2911–E2919.

18. Rossi D., Spina V., Cerri M. et al. Stereotyped B­cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome // Clin. Cancer Res. 2009. Vol. 15. P. 4415–4422.

19. Gounari M., Ntoufa S., Apollonio B. et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8 // Blood. 2015. Vol. 125, N 23. P. 3580–3587.

20. Kadri S., Lee J., Fitzpatrick C. et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib­relapsed CLL // Blood Adv. 2017. Vol. 1, N 12. P. 715–727.

21. Maddocks K.J., Ruppert A.S., Lozanski G. et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia // JAMA Oncol. 2015. Vol. 1, N 1. P. 80–87.

22. Rossi D., Rasi S., Spina V. et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome // Br. J. Haematol. 2012. Vol. 158. P. 426–429.

23. Villamor N., Conde L., Martínez­Trillos A. et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome // Leukemia. 2013. Vol. 27. P. 1100–1106.

24. Rossi D., Rasi S., Fabbri G. et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia // Blood. 2012. Vol. 119. P. 521–529.

25. Stilgenbauer S., Schnaiter A., Paschka P. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254.

26. Miller C.R., Ruppert A.S., Heerema N.A. et al. Near­tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib // Blood Adv. 2017. Vol. 1, N 19. P. 1584–1588.

27. Rossi D., Cerri M., Capello D. et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome // Br. J. Haematol. 2008. Vol. 142, N 2. P. 202–215.

28. Catovsky D., Richards S., Matutes E. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial // Lancet. 2007. Vol. 370. P. 230–239.

29. Solh M., Rai K.R., Peterson B.L. et al. The impact of initial fludarabine therapy on transformation to Richter’s syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011) // Leuk. Lymphoma. 2013. Vol. 54. P. 252–254.

30. Fischer K., Bahlo J., Fink A.M. et al. Long­term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial // Blood. 2016. Vol. 127, N 2. P. 208–215.

31. Byrd J.C., Furman R.R., Coutre S.E. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2013. Vol. 369. P. 32–42.

32. Byrd J.C., Brown J.R., O’Brien S. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia // N. Engl. J. Med. 2014. Vol. 371. P. 213–223.

33. O’Brien S., Furman R.R., Coutre S.E. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open­label, multicentre, phase 1b/2 trial // Lancet Oncol. 2014. Vol. 15. P. 48–58.

34. Strati P., Keating M.J., O’Brien S.M. et al. Outcomes of first­line treatment for chronic lymphocytic leukemia with 17p deletion // Haematologica. 2014. Vol. 99. P. 1350–1355.

35. Farooqui M.Z., Valdez J., Martyr S. et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single­arm trial // Lancet Oncol. 2015. Vol. 16. P. 169–176.

36. Jain P., Keating M., Wierda W. et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib // Blood. 2015. Vol. 125. P. 2062–2067.

37. Mato A.R., Nabhan C., Barr P.M. et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience // Blood. 2016. Vol. 128, N 18. P. 2199–2205.

38. Roberts A.W., Davids M.S., Pagel J.M. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 311–322.

39. Furman R.R., Sharman J.P., Coutre S.E. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2014. Vol. 370, N 11. P. 997–1007.

40. Seymour J.F., Kipps T.J., Eichhorst B.F. et al. Venetoclax Plus Rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia – results from pre­planned interim analysis of the randomized phase 3 MURANO study // Blood. 2017. Vol. 130. Abstr. LBA­2.

41. Khan M., Siddiqi R., Thompson R.A. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies // Ann. Hematol. 2018. Vol. 97, N 1. P. 1–15.

42. Robertson L.E., Pugh W., O’Brien S. et al. Richter’s syndrome: a report on 39 patients // J. Clin. Oncol. 1993. Vol. 11. P. 1985–1989.

43. Bruzzi J.F., Macapinlac H., Tsimberidou A.M. et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT // J. Nucl. Med. 2006. Vol. 47. P. 1267–1273.

44. Falchi L., Keating M.J., Marom E.M. et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia // Blood. 2014. Vol. 123, N 18. P. 2783–2790.

45. Mauro F.R., Chauvie S., Paoloni F. et al. Diagnostic and prognostic role of ПЭТ/КТ in patients with chronic lymphocytic leukemia and progressive disease // Leukemia. 2015. Vol. 29, N 6. P. 1360–1365.

46. Rogers K.A., Huang Y., Ruppert A.S. et al. A single­institution retrospective cohort study of first­line R­EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor // Br. J. Haematol. 2018. Vol. 180, N 2. P. 259–266. DOI: https://doi.org/10.1111/bjh.15035

47. Mato A.R., Wierda W.G., Davids M.S. et al. Analysis of PET­CT to identify Richter’s transformation in 167 patients with disease progression following kinase inhibitor therapy // Blood. 2017. Vol. 130. P. 834.

48. Porrazzo M., Nicolai E., Riminucci M. et al. Prognostic significance of ПЭТ/КТ in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy // Cancers (Basel). 2020. Vol. 12, N 7. P. 1773.

49. Gascoyne R.D. XIV. The pathology of transformation of indolent B cell lymphomas // Hematol. Oncol. 2015. Vol. 33, suppl. 1. P. 75–79.

50. Tsimberidou A.­M., O’Brien S., Khouri I. et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem­cell transplantation // J. Clin. Oncol. 2006. Vol. 24. P. 2343–2351.

51. Abrisqueta P., Delgado J., Alcoceba M. et al. Clinical outcome and prognostic factors of patients with Richter’s syndrome: retrospective multicenter study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC) // Blood. 2017. Vol. 130. P. 2995.

52. Parikh S.A., Kay N.E., Shanafelt T.D. How we treat Richter syndrome // Blood. 2014. Vol. 123, N 11. P. 1647–1657.

53. Jain P., Thompson P.A., Keating M. et al. Long­term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib // Cancer. 2017. Vol. 123, N 12. P. 2268–2273. DOI: https://doi.org/10.1002/cncr.30596.

54. Byrd J.C., Blum K.A., Burger J.A. et al. Activity and tolerability of the Bruton’s tyrosine kinase (Btk) inhibitor PCI­32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study // J. Clin. Oncol. 2011. Vol. 29, N 15. Suppl. P. 6508–6508.

55. Langerbeins P., Busch R., Anheier N. et al. Poor efficacy and tolerability of R­CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation // Am. J. Hematol. 2014. Vol. 89. P. E239–E243.